Inferra AIResearch Tools

Inferra AI / Company / VKTX

Viking Therapeutics, Inc.

VKTX · Health Care

Last earnings Oct 28, 2026

AI analysis

Q3 2025 · reported Oct 22, 2025

Based on: Earnings release + parent 8-K — transcript not held

No extracted figures held

The event-summary record for this company carries no extracted figures, so the brief and charts cannot be drawn yet. The summary below and the held documents are the record for this event.

Guidance · company-stated

No guidance located in the held release

Next earningsNo verified date on fileNo date is estimated or imported
General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

No guidance located in the held release

Strategy & priorities

(Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2025, and provided an update on its clinical pipeline and other corporate developments.

SEC original ↗Viking Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Oct 22, 2025

The company is also encouraged by the results from the exploratory maintenance arm of this study, which provides support for transitioning patients from higher doses to low oral doses as a potentially effective maintenance strategy.

SEC original ↗Viking Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Oct 22, 2025

is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders.

SEC original ↗Viking Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Oct 22, 2025

com Vida Strategic Partners Stephanie Diaz (Investors) 415-675-7401 sdiaz@vidasp.

SEC original ↗Viking Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Oct 22, 2025

Risks & headwinds

The company believes this may mitigate potential safety or tolerability challenges that can occur when transitioning patients from one treatment to another.

SEC original ↗Viking Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Oct 22, 2025

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance.

SEC original ↗Viking Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Oct 22, 2025

Documents

Earnings deck slides

4 decks with slide view

Viking Therapeutics, Inc. — Viking+Therapeutics+Corporate+Presentation+October+2026+ +Revised+slide+6+102526 (company IR deck) — Slide view unavailable — the original PDF could not be retrieved for segmentation (HTTP Error 404: Not Found).

Slide history — recurring slides by stated title

Slides are matched across this company’s decks by their stated title only; a title listed here appeared in more than one held deck.

Forward-Looking Statements — Oct 28, 2026 · slide 2 · Oct 28, 2026 · slide 2 · Oct 28, 2026 · slide 2

Corporate Presentation — Oct 28, 2026 · slide 1 · Oct 28, 2026 · slide 1

Discontinuation and GI Tolerability Summary – Every Other Week — Oct 28, 2026 · slide 41 · Oct 28, 2026 · slide 11

Financial Summary — Oct 28, 2026 · slide 49 · Oct 28, 2026 · slide 33

GI AEs Generally Observed Early and Subside Over Time — Oct 28, 2026 · slide 28 · Oct 28, 2026 · slide 20

Maintenance Study: 17.5 mg Weekly Dosing Provides Highly — Oct 28, 2026 · slide 39 · Oct 28, 2026 · slide 9

Maintenance Study: Induction Weight Loss Through Week 21 — Oct 28, 2026 · slide 35 · Oct 28, 2026 · slide 5

Maintenance Study: Maintenance of Weight Loss with Every- — Oct 28, 2026 · slide 37 · Oct 28, 2026 · slide 7

Maintenance Study: Maintenance of Weight Loss with Monthly — Oct 28, 2026 · slide 38 · Oct 28, 2026 · slide 8

VANQUISH Phase 3 Study Design — Oct 28, 2026 · slide 19 · Oct 28, 2026 · slide 31

VENTURE Phase 2 Study: GI Tolerability Summary — Oct 28, 2026 · slide 16 · Oct 28, 2026 · slide 27

VK2735 Oral Phase 2 Study: GI Tolerability Summary — Oct 28, 2026 · slide 27 · Oct 28, 2026 · slide 19

VK2735 Oral Tablet Formulation + — Oct 28, 2026 · slide 20 · Oct 28, 2026 · slide 9

VK2735 Subcutaneous Formulation — Oct 28, 2026 · slide 8 · Oct 28, 2026 · slide 22

VK2735 Subcutaneous: VANQUISH Phase 3 Overview — Oct 28, 2026 · slide 18 · Oct 28, 2026 · slide 30

VK2735-102 Study Establishes Maintenance Use Case — Oct 28, 2026 · slide 43 · Oct 28, 2026 · slide 13

VK2735-102: Maintenance Study Design — Oct 28, 2026 · slide 34 · Oct 28, 2026 · slide 4

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

33 documents

Earnings releases

24 documents

Presentations

5 documents

Transcripts

0 documents

No transcripts for Viking Therapeutics, Inc. are held in this edition of the library.

See also the earnings calendar for every tracked company’s next earnings date.